Kolon Tissuegene’s Invossa gets second chance as FDA removes clinical hold April 16, 2020 By Gina Lee No Comments HONG KONG – South Korean biopharmaceutical company Kolon Tissuegene Inc. got a new lease on life as the U.S. FDA lifted the hold on the phase III trial for its lead candidate, Invossa-K (Invossa), for the treatment of osteoarthritis.Read More